Spondyloarthritis & psoriatic arthritis
Biologic switching in psoriatic arthritis: Insights from real-world data and key risk factors
Authors' conclusion
Cross class biologic switching is common in PsA management (48 %) and influenced by patient demographics and comorbidities. Switching patterns were consistent across time periods despite expanding therapeutic options.
Study context
- Population
- Psoriatic arthritis (PsA) patients in Israel initiating biologic disease-modifying antirheumatic drugs (bDMARDs), Clalit Health Services database (2005–2023)initiating bDMARDs, of 9607 PsA patients
- Participants
- 3,851 patients
- Exposure
- Switchers vs non-switchers of bDMARD therapy
- Switchersn = 1,848
- Outcome
- Switching of bDMARD therapy at least once
Methodological detailsClalit Health Services database (2005-2023), multivariate analysis
- Clalit Health Services database (2005-2023)
- Multivariate analysis
Main finding
As reported in the abstract
Switched bDMARD therapy at least once
Switchers
48 %
1848
Observational data: associations, not effects.
Further findings
Female
P < 0.001
Obese
P < 0.001
Smokers
P = 0.005
Lower socioeconomic background
P = 0.04
- Female: independently associated with switching in mechanism of action on multivariate analysis
- Obese: independently associated with switching in mechanism of action on multivariate analysis
- Smokers: independently associated with switching in mechanism of action on multivariate analysis
- Lower socioeconomic background: independently associated with switching in mechanism of action on multivariate analysis
Original publication
Biologic switching in psoriatic arthritis: Insights from real-world data and key risk factors. Semin Arthritis Rheum. Published 17 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →